This is a working overview of fatty diacid chain, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Christopher Richard Stein (born 4 January 1947) is an English celebrity chef, restaurateur, writer and television presenter. Along with business partner and first wife Jill Stein, he runs the Stein hotel and restaurant business in the UK. The business has a number of renowned restaurants, shops and hotels in Padstow along with other restaurants in Winchester and Barnes. He is the head chef and a co-owner of the Rick Stein at Bannisters restaurants in Mollymook and Port Stephens in Australia, with his second wife, Sarah. He writes cookery books and has presented numerous cookery series for the BBC.
Using the Hierarchy of Controls, there are various methods of preventing exposure to respirable crystalline silica. The best way to prevent silicosis is to avoid worker exposure to dust containing respirable crystalline silica. The next best preventive measure is to control the dust. Water-integrated tools are often used where dust is created during certain tasks. To avoid dust accumulating on clothing and skin, wear a disposable protective suit or seal clothes in an airtight bag and, if possible, shower once returning home. When dust starts accumulating around a workplace, and the use of water-integrated tools is not feasible, an industrial vacuum should be used to contain and transport dust to a safe location for disposal. Dust can also be controlled through personal dry air filtering. The use of personal protective equipment (PPE) is a measure of last resort when attempting to control exposure to respirable crystalline silica. Preventing silicosis may require specific measures. One example is during tunnel construction where purpose-designed cabins are used in addition to air scrubbers to filter the air during construction. Items to be considered when selecting respiratory protection include whether it provides the correct level of protection, if facial fit testing has been provided, if the wearer is absent of facial hair, and how filters will be replaced.
In the widely used Couinaud system, the functional lobes are further divided into a total of eight subsegments based on a transverse plane through the bifurcation of the main portal vein. The caudate lobe is a separate structure that receives blood flow from both the right- and left-sided vascular branches. The Couinaud classification divides the liver into eight functionally independent liver segments. Each segment has its own vascular inflow, outflow and biliary drainage. In the centre of each segment are branches of the portal vein, hepatic artery, and bile duct. In the periphery of each segment is vascular outflow through the hepatic veins. The classification system uses the vascular supply in the liver to separate the functional units (numbered I to VIII) with unit 1, the caudate lobe, receiving its supply from both the right and the left branches of the portal vein. It contains one or more hepatic veins which drain directly into the inferior vena cava. The remainder of the units (II to VIII) are numbered in a clockwise fashion:
=== Biochemical synthesis === Glycocyamine is formed in the mammalian organism primarily in the kidneys by transferring the guanidine group of L-arginine by the enzyme L-Arg:Gly-amidinotransferase (AGAT) to the amino acid glycine. From L-arginine, ornithine is thus produced, which is metabolized in the urea cycle by carbamoylation to citrulline.
This principle of self-determination had been declared on numerous occasions subsequent to the declaration – President Wilson's January 1918 Fourteen Points, Sykes's Declaration to the Seven in June 1918, the November 1918 Anglo-French Declaration, and the June 1919 Covenant of the League of Nations that had established the mandate system. In an August 1919 memo Balfour acknowledged the inconsistency among these statements, and further explained that the British had no intention of consulting the existing population of Palestine. The results of the ongoing American King–Crane Commission of Enquiry consultation of the local population – from which the British had withdrawn – were suppressed for three years until the report was leaked in 1922. Subsequent British governments have acknowledged this deficiency, in particular the 1939 committee led by the Lord Chancellor, Frederic Maugham, which concluded that the government had not been "free to dispose of Palestine without regard for the wishes and interests of the inhabitants of Palestine", and the April 2017 statement by British Foreign Office minister of state Baroness Anelay that the government acknowledged that "the Declaration should have called for the protection of political rights of the non-Jewish communities in Palestine, particularly their right to self-determination."
Sources: en.wikipedia.org
== Structure == The GSTK1 enzyme is a homodimer and, like all GSTs, it contains a TRX-like domain and a helical domain. However, the GSTK1 is substantially different in its secondary structure compared to the other GSTs. The helical domain has been observed to be placed between the βαβ and ββα motifs of the TRX-like domain, rather than the TRX-like domain and the C-terminal helical domain being connected together by a short linker of alpha-helixes as normally seen in GSTs. Also, the GSTK1 dimer employs a butterfly shape and not a V-shaped crevice like in the other classes. As for the GSTK1 gene, it is ~5 kb long, has eight exons, is located on chromosome 7q34, and includes an initiator element at the transcription start site instead of a TATA or a CCAAT box.
In late 1999, al-Qaeda associate Walid bin Attash ("Khallad") contacted al-Mihdhar and told him to meet in Kuala Lumpur, Malaysia; al-Hazmi and Abu Bara al Yemeni would also be in attendance. The NSA intercepted a telephone call mentioning the meeting, al-Mihdhar, and the name "Nawaf" (al-Hazmi); while the agency feared "Something nefarious might be afoot", it took no further action. The CIA had already been alerted by Saudi intelligence about al-Mihdhar and al-Hazmi being al-Qaeda members. A CIA team broke into al-Mihdhar's Dubai hotel room and discovered that Mihdhar had a U.S. visa. While Alec Station alerted intelligence agencies worldwide, it did not share this information with the FBI. The Malaysian Special Branch observed the January 5, 2000, meeting of the two al-Qaeda members and informed the CIA that al-Mihdhar, al-Hazmi, and Khallad were flying to Bangkok, but the CIA never notified other agencies of this, nor did it ask the State Department to put al-Mihdhar on its watchlist. An FBI liaison asked permission to inform the FBI of the meeting but was told: "This is not a matter for the FBI."
=== Dyeing === A natural purple dye extracted from Parmotrema perlatum using ammonia fermentation showed optimal results, with a notable dye yield and effective application on silk fabric. The study demonstrated the dye's potential as a sustainable alternative to synthetic dyes, with satisfactory colour fastness and fabric strength enhancement. Recent research highlights the antimicrobial, antioxidant, and photocatalytic capabilities of zinc oxide nanoparticles synthesised using Parmotrema perlatum, marking a significant step towards sustainable dyeing practices and broadening the lichen's applicative horizons.
== Governance == The South African Government department most related to the country's logistics sector is the Department of Transport (DoT). In 2023, the DoT released a Roadmap for the Freight Logistics System in South Africa. In the document, the government outlined that while it believed that strategic infrastructure such as rail and ports would remain publicly-owned, as it belongs to the people of South Africa, operating of such infrastructure could be opened up to private investment. Doing so, the government believes, will allow for increased efficiencies and competitiveness. The roadmap serves as a guide for state-owned transit company Transnet to achieve this balance, translating policy commitments into actions that are to be taken by the entity. In 2025, one of the themes of the Department of Transport's budget was facilitating the development of the country's air cargo capacity. Part of a R21.7-billion Airports Company South Africa (ACSA) infrastructure development allocation was set aside for increasing air freight handling through its network of airports. South Africa's fuel pipelines are regulated by the National Energy Regulator of South Africa (NERSA).
One night, she ends up at a bar where her father works. After getting into an altercation with a man at the bar, she vents her frustrations at her father (who prevents her from driving home), claiming she is like him; however, she stays the night at her father's place and reconnects with him; he says she's not like him but is like her mother. Ryan later gets hurt and is discharged, and Amber goes to visit him in the hospital, but Ryan's mother shows up and insists he return to Wyoming. Later, Amber finds out she is pregnant with Ryan's child. However, she exhibits a strong want to raise the child on her own without his help (especially after talking with Drew, who drove her to Wyoming so she could give the news to Ryan and refused to leave her there). In the penultimate episode of the series, Amber gives birth to a son, whom she names Ezekiel (Zeek) after her grandfather. Because she is struggling in her small apartment, Zeek and Camille invite Amber and her baby to move in with them, to which she happily agrees. After an undisclosed amount of time, Amber is now married to a man with whom she has a young daughter, while Ryan remains a part of his son's life.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.